A Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D

NCT ID: NCT06505928

Last Updated: 2025-12-23

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 90 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-12-11
• Study Completion Date: 2026-07-31

Brief Summary

The goal of this clinical trial is to evaluate the efficacy and safety of L47 in the treatment of chronic hepatitis D. Patients with compensated CHD who satisfy the eligibility criteria are stratified by the presence or absence of liver cirrhosis and randomized into three groups at a 1:1:1 ratio. The subjects will receive continuous L47 (2.1 mg/d and 4.2 mg/d, s.c.) treatment for 48 weeks (groups A and B), or delayed treatment for 48 weeks (group C). Primary endpoint evaluation will be performed after the subjects complete the 48-week treatment.

Detailed Description

This is a three-arm, parallel-group, randomized, open-label, delayed-controlled phase IIb clinical trial. The study flow chart is shown in Fig. 1.2.1. CHD patients with compensated liver function who satisfy the eligibility criteria are stratified by the presence or absence of liver cirrhosis and randomized into the 2.1 mg group, 4.2 mg group, and delayed treatment group at a 1:1:1 ratio (Table 1.1). The subjects will receive continuous L47 (2.1 mg/d and 4.2 mg/d, s.c.) treatment for 48 weeks (groups A and B), or delayed treatment for 48 weeks (group C). The 1st interim analysis will be performed when all subjects complete the Week12 visit to determine the optimal dose for the extended treatment period following the trial. The 2nd interim analysis will be performed when all subjects complete the Week24 visit. Upon completion of the 48th week of treatment, the primary endpoint was assessed, and the trial was officially concluded.

After the conclusion of the trial, all subjects in each group entered the extension treatment period and were all treated continuously with the L47 optimal dose for 96 weeks. After the extension treatment ended, all groups discontinued the medication and were observed for 48 weeks follow-up.

Conditions

Hepatitis D

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Hepalatide 2.1mg

hepalatide 2.1mg/d, s.c. for 48 weeks

Group Type: EXPERIMENTAL

hepalatide

Intervention Type: DRUG

hepalatide of 2.1 mg/d or 4.2mg/d s.c. treatment for 48 weeks

Hepalatide 4.2mg

hepalatide 4.2mg/d, s.c. for 48 weeks

Group Type: EXPERIMENTAL

hepalatide

Intervention Type: DRUG

hepalatide of 2.1 mg/d or 4.2mg/d s.c. treatment for 48 weeks

delayed treatment groups

delayed treatment for 48 weeks

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

hepalatide

hepalatide of 2.1 mg/d or 4.2mg/d s.c. treatment for 48 weeks

Intervention Type: DRUG

Other Intervention Names

L47

Eligibility Criteria

Inclusion Criteria

• 1. Male or female subjects aged 18-65 years (both inclusive);
• 2. Subjects with positive HBsAg and/or HBV DNA for at least 6 months ("CHB");
• 3. Subjects with positive serum anti-HDV antibody before or at screening or with positive HDV RNA for at least 6 months before screening ("CHD");
• 4. Subjects with positive and quantifiable HDV RNA before enrollment;
• 5. 1 × ULN < ALT < 10 × ULN;
• 6. Subjects who should be treated with nucleoside/nucleotide reverse transcriptase inhibitors at enrollment or after enrollment according to the guidelines for the treatment of hepatitis D (compensated cirrhosis with detectable HBV DNA, or HBV DNA > 2000 IU/mL in patients without cirrhosis) and consent to the use of entecavir for the treatment of chronic hepatitis B;
• 7. Subjects who do not plan a pregnancy within 3 years (women who are not pregnant or lactating, and males who agree to take effective contraceptive measures throughout the treatment period and for 3 months after the last dose);
• 8. Subjects exhibiting good compliance to the study protocol;
• 9. Subjects who understand the ICF and agree to sign it.

Exclusion Criteria

• 1. Subjects suffering from severe decompensated liver fibrosis or decompensated liver cirrhosis with a Child-Pugh score > 7;
• 2. Decompensated liver disease: Direct bilirubin > 1.2 x ULN or prothrombin time > 1.2 x ULN or serum albumin < 35 g/L;
• 3. Abnormal hematology findings: White blood cell count (WBC) < 3 × 109/L, neutrophil count < 1.5 × 109/L or platelet count < 60 × 109/L;
• 4. Creatinine clearance < 60 mL/min;
• 5. Subjects who have any of the following conditions:

1. History of current or past decompensated liver diseases (including coagulopathy, hepatic encephalopathy, and variceal bleeding);

2. Comorbidity of underlying diseases such as severe infection, heart failure and chronic obstructive pulmonary disease, and other severe diseases;

3. Diabetes mellitus and hypertension not effectively controlled (systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg);

4. Current or previous uncontrolled epilepsy or psychiatric disorders;

5. History of solid organ transplantation;

6. Evidence of active or suspected malignancies or history of malignancies, or untreated premalignant lesions within the past 5 years (except for successfully treated cervical carcinoma in situ at least 1 year before screening, and successfully treated basal cell carcinoma and squamous cell carcinoma [≤ 3 cases of resected skin cancer within 5 years before screening ]), or history of liver cancer;

7. History of alcohol abuse or drug addiction at present or within 6 months prior to participation in this study; 6. Subjects co-infected with hepatitis A, C, or E virus or with uncontrolled HIV co-infection (those with positive HCV antibody but negative HCV RNA at screening are eligible for enrollment. HIV-infected patients may be enrolled if cluster of differentiation 4 (CD4) cell count is > 500/mL and HIV RNA is below the limit of detection for at least 12 months);

• 7. Presence of one or more other known primary or secondary liver diseases, such as alcoholism, autoimmune hepatitis, malignancies involving the liver, hemochromatosis, other congenital or metabolic diseases affecting the liver, congestive heart failure, or other serious cardiopulmonary diseases, excluding hepatitis B;
• 8. Subjects with one or more autoimmune diseases, immune-related extrahepatic manifestations (such as vasculitis, purpura, arteritis nodosa, peripheral neuropathy, and glomerulonephritis), or a history of requiring regular use of systemic corticosteroids (inhaled corticosteroids are allowed) or other immunosuppressive agents;
• 9. Subjects who have used interferon within 6 months before screening;
• 10. Subjects who have used L47 or Bulevirtide within 3 months;
• 11. Allergy to entecavir;
• 12. Pregnant or breastfeeding women;
• 13. Subjects who participated in other drug clinical trials within 30 days before randomization;
• 14. Subjects who are receiving prohibited treatment at screening that cannot be discontinued;
• 15. Subjects who cannot comply with the study protocol and complete all procedures as scheduled, or have significant abnormalities in other laboratory or auxiliary examinations, which render them ineligible for this trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shanghai HEP Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Oyunbileg Janchiv

Role: PRINCIPAL_INVESTIGATOR

National Cacer Center of Monglia

Locations

National cancer canter of Monglia

Ulaanbaatar, , Mongolia

National Center for Communicable Diseases

Ulaanbaatar, , Mongolia

Countries

Mongolia

Other Identifiers

L47-HD-MN

Identifier Type: -

Identifier Source: org_study_id